Literature DB >> 3219148

Pharmacological actions of benidipine hydrochloride in several isolated smooth muscles and myocardium.

A Karasawa1, K Kubo, K Shuto, T Oka, N Nakamizo.   

Abstract

Using various isolated smooth muscles and myocardium, the calcium antagonistic effect of (+/-)-(R*)-2,6-dimethyl-4-(m-nitrophenyl)- 1,4-dihydropyridine-3,5-dicarboxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049), and its specificity were examined. Furthermore, the in vitro duration of action and the antispasmodic actions in coronary arteries were investigated in comparison with those of nifedipine, verapamil and diltiazem. 1. Ca antagonisms of KW-3049 When the Ca antagonistic effect of KW-3049 was investigated, for which the contractile responses to KCl in isolated mesenteric arteries in rabbits were taken as an indicator, the activity of KW-3049 was of about the same degree as nifedipine and approx. 30 times greater than those of verapamil and diltiazem. On the other hand, the negative inotropic action in isolated atria in rabbits was weaker than that of nifedipine. 2. Influences on responses to various agonists From the investigations using various isolated organs, it was evident that KW-3049 had neither agonistic nor antagonistic actions or very weak actions on the following receptors: alpha 1, alpha 2, beta 1, beta 2, H1, H2, muscarinic acetylcholine, 5HT2, angiotensin II, and prostaglandin F2 alpha. 3. Duration of in vitro actions Inhibitory actions of KW-3049 on 55 mmol/l-induced contractions in isolated mesenteric arteries in rabbits persisted even 180 min after the removal of drug solution and the repeated wash-out of tissues. On the other hand, those of nifedipine, verapamil and diltiazem disappeared within 60 to 120 min.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3219148

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.

Authors:  Mauro Cataldi; Fiorentina Bruno
Journal:  Transl Med UniSa       Date:  2012-10-11

2.  T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney disease.

Authors:  Masanori Abe; Kazuyoshi Okada; Hiroko Suzuki; Yoshinori Yoshida; Masayoshi Soma
Journal:  BMC Nephrol       Date:  2013-07-01       Impact factor: 2.388

3.  Inhibition by Benidipine of Contractility of Isolated Proximal and Distal Caprine Ureter.

Authors:  Sumith K Mathew; Girish S Naik; Jacob Peedicayil
Journal:  Int J Appl Basic Med Res       Date:  2017 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.